Changes in Tumor Vascularity Depicted by Contrast-enhanced EUS As a Predictor of Prognosis and Treatment Efficacy in Patients with Unresectable Pancreatic Cancer (PEACE): A Study Protocol

Overview

Journal Endosc Ultrasound

Date 2019 Jun 29

PMID 31249159

Citations 10

Authors

Adrian Saftoiu

Manoop S Bhutani

Takao Itoi

Paolo G Arcidiacono

Erwan Bories

Irina M Cazacu

Alina Constantin

Emmanuel Coronel

Christoph F Dietrich

Dan G Duda

Julio Iglesias Garcia

Michael Hocke

Andre Ignee

Christian Jenssen

Mariana Jinga

Christopher Khor

Kofi W Oppong

Stephen Pereira

Maria Chiara Petrone

Erwin Santo

Andrada Seicean

Dong Wan Seo

Sun Siyu

Peter Vilmann

Irving Waxman

Paul Yeaton

Affiliations

Soon will be listed here.

Abstract

Patients with unresectable pancreatic cancer have a poor prognosis. The analysis of prognostic factors before treatment may be helpful in determining the best therapeutic strategies. The aim of the PEACE study is to assess the vascularity of pancreatic malignant tumors using contrast-enhanced harmonic EUS (CEH-EUS) and to clarify the prognostic value of tumor vascularity in patients with locally advanced and metastatic pancreatic cancer. Hereby, we present the protocol of a prospective, nonrandomized, single-arm, multicenter study aiming to assess changes in tumor vascularity using CEH-EUS before and 2 months after treatment initiation in patients with unresectable, locally advanced/metastatic pancreatic cancer and to examine the correlation between vascular changes and treatment response, progression-free survival, and overall survival.

Citing Articles

Impact of osteopenia and osteosarcopenia on the outcomes after surgery of hepatobiliary-pancreatic cancers.

Wang X, Wu M, Liu Q, He W, Tian Y, Zhang Y Front Oncol. 2024; 14:1403822.

PMID: 39099698 PMC: 11294096. DOI: 10.3389/fonc.2024.1403822.

Clinical value of endoscopic ultrasound sound speed in differential diagnosis of pancreatic solid lesion and prognosis of pancreatic cancer.

Qiu J, Li K, Long X, Yu X, Gong P, Long Y Cancer Med. 2024; 13(5):e7026.

PMID: 38477492 PMC: 10935872. DOI: 10.1002/cam4.7026.

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.

Kamiya T, Imai H, Fujita Y, Hiruta E, Masuno T, Yamazaki S Medicina (Kaunas). 2023; 59(3).

PMID: 36984494 PMC: 10051263. DOI: 10.3390/medicina59030492.

Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound.

Lu X, Guo X, Zhang Q, Qiu Y, Zuo D, Chen S Diagnostics (Basel). 2022; 12(11).

PMID: 36359506 PMC: 9689529. DOI: 10.3390/diagnostics12112662.

Advanced EUS Imaging Techniques.

Cazacu I, Saftoiu A, Bhutani M Dig Dis Sci. 2022; 67(5):1588-1598.

PMID: 35451709 DOI: 10.1007/s10620-022-07486-9.

References

Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A . Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999; 79(9-10):1553-63. PMC: 2362700. DOI: 10.1038/sj.bjc.6690248. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Masaki T, Ohkawa S, Amano A, Ueno M, Miyakawa K, Tarao K . Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer. 2005; 103(5):1026-35. DOI: 10.1002/cncr.20875. View

Zhang X, Galardi E, Duquette M, Lawler J, Parangi S . Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res. 2005; 11(15):5622-30. DOI: 10.1158/1078-0432.CCR-05-0459. View

Dietrich C, Ignee A, Frey H . Contrast-enhanced endoscopic ultrasound with low mechanical index: a new technique. Z Gastroenterol. 2005; 43(11):1219-23. DOI: 10.1055/s-2005-858662. View

Lowenfels A, Maisonneuve P . Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20(2):197-209. DOI: 10.1016/j.bpg.2005.10.001. View

Folkman J . What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990; 82(1):4-6. DOI: 10.1093/jnci/82.1.4. View

Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F . Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med. 2008; 29(1):28-44. DOI: 10.1055/s-2007-963785. View

Sofuni A, Itoi T, Itokawa F, Tsuchiya T, Kurihara T, Ishii K . Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. World J Gastroenterol. 2008; 14(47):7183-91. PMC: 2776876. DOI: 10.3748/wjg.14.7183. View

10.

Sanchez M, Varadarajulu S, Napoleon B . EUS contrast agents: what is available, how do they work, and are they effective?. Gastrointest Endosc. 2009; 69(2 Suppl):S71-7. DOI: 10.1016/j.gie.2008.12.004. View

11.

Seicean A, Badea R, Stan-Iuga R, Gulei I, Pop T, Pascu O . The added value of real-time harmonics contrast-enhanced endoscopic ultrasonography for the characterisation of pancreatic diseases in routine practice. J Gastrointestin Liver Dis. 2010; 19(1):99-104. View

12.

Fusaroli P, Spada A, Mancino M, Caletti G . Contrast harmonic echo-endoscopic ultrasound improves accuracy in diagnosis of solid pancreatic masses. Clin Gastroenterol Hepatol. 2010; 8(7):629-34.e1-2. DOI: 10.1016/j.cgh.2010.04.012. View

13.

Napoleon B, Alvarez-Sanchez M, Gincoul R, Pujol B, Lefort C, Lepilliez V . Contrast-enhanced harmonic endoscopic ultrasound in solid lesions of the pancreas: results of a pilot study. Endoscopy. 2010; 42(7):564-70. DOI: 10.1055/s-0030-1255537. View

14.

Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O . Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med. 2010; 31(6):571-6. DOI: 10.1055/s-0029-1245833. View

15.

Bao B, Ali S, Ahmad A, Azmi A, Li Y, Banerjee S . Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One. 2012; 7(12):e50165. PMC: 3521759. DOI: 10.1371/journal.pone.0050165. View

16.

Yamashita Y, Ueda K, Itonaga M, Yoshida T, Maeda H, Maekita T . Tumor vessel depiction with contrast-enhanced endoscopic ultrasonography predicts efficacy of chemotherapy in pancreatic cancer. Pancreas. 2013; 42(6):990-5. DOI: 10.1097/MPA.0b013e31827fe94c. View

17.

Chauhan V, Martin J, Liu H, Lacorre D, Jain S, Kozin S . Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013; 4:2516. PMC: 3806395. DOI: 10.1038/ncomms3516. View

18.

Saftoiu A, Vilmann P, Bhutani M . The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. Endosc Ultrasound. 2016; 5(6):368-372. PMC: 5206824. DOI: 10.4103/2303-9027.190932. View

19.

Fidler I, Ellis L . The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994; 79(2):185-8. DOI: 10.1016/0092-8674(94)90187-2. View

20.

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View